Evidence map›Paper›PMID 38737300›Full record

SynthesisTremor and other hyperkinetic movements (New York, N.Y.)2024

Drug- and Toxin-Induced Opsoclonus - a Systematized Review, including a Case Report on Amantadine-Induced Opsoclonus in Multiple System Atrophy.

Hugo Cannilla, Maria Messe, François Girardin, François-Xavier Borruat, Julien F Bally

Abstract readCase ReportsSystematic Review
In one paragraph

Synthesis in Tremor and other hyperkinetic movements (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Opsoclonus-Myoclonus: Not Always Paraneoplastic.Movement disorders clinical practice · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hugo CannillaUniversity of Lausanne, Lausanne, Switzerland.
Maria MesseGeneva University Hospitals and University of Geneva, Geneva, Switzerland.
François GirardinDepartment of ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0842-927X
François-Xavier BorruatDepartment of ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3237-3800
Julien F BallyService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0970-8844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Opsoclonus is a rare disorder characterized by conjugate multidirectional, horizontal, vertical, and torsional saccadic oscillations, without intersaccadic interval, resulting from dysfunction within complex neuronal pathways in the brainstem and cerebellum. While most cases of opsoclonus are associated with autoimmune or paraneoplastic disorders, infectious agents, trauma, or remain idiopathic, opsoclonus can also be caused by medications affecting neurotransmission. This review was prompted by a case of opsoclonus occurring in a patient with Multiple System Atrophy, where amantadine, an NMDA-receptor antagonist, appeared to induce opsoclonus. Methods: Case report of a single patient and systematized review of toxic/drug-induced opsoclonus, selecting articles based on predefined criteria and assessing the quality of included studies. Results: The review included 30 articles encompassing 158 cases of toxic/drug-induced opsoclonus. 74% of cases were attributed to bark scorpion poisoning, followed by 9% of cases associated with chlordecone intoxication. The remaining cases were due to various toxics/drugs, highlighting the involvement of various neurotransmitters, including acetylcholine, glutamate, GABA, dopamine, glycine, and sodium channels, in the development of opsoclonus. Conclusion: Toxic/drug-induced opsoclonus is very rare. The diversity of toxics/drugs impacting different neurotransmitter systems makes it challenging to define a unifying mechanism, given the intricate neuronal pathways underlying eye movement physiology and opsoclonus pathophysiology.

Indexed as

AmantadineMultiple System AtrophyOcular Motility DisordersAgedHumansMaleAmantadineDrug Adverse effectsDrug-inducedMultiple system atrophyOpsoclonusOpsoclonus-Myoclonus Syndrome

Identifiers

PMID38737300
PMCPMC11086588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.